A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
Abstract
:1. Introduction
2. Results
2.1. Passaging of MVA in Suspension Cultures
2.2. Confirmation Experiments.
2.3. Higher Proportion of Infectious Units in the Cell-Free Space.
2.4. Specificity for Suspension Process.
2.5. Maintenance of Host-Cell Restriction of MVA-CR
3. Experimental Section
3.1. Cells and Viruses
3.2. Titration
3.3. Plaque Purification
3.4. Plaque Phenotype
3.5. DNA and Sequencing
4. Discussion and Conclusions
4.1. Enrichment of a New Genotyp
4.2. Extracellular Infectious Units
4.3. Attenuation on R05T
Conflict of Interest
References
- Kemper, A.R.; Davis, M.M.; Freed, G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002, 5, 84–90. [Google Scholar]
- Parrino, J.; Graham, B.S. Smallpox vaccines: Past, present, and future. J. Allergy Clin. Immunol. 2006, 118, 1320–1326. [Google Scholar] [CrossRef]
- Zurbriggen, S.; Tobler, K.; Abril, C.; Diedrich, S.; Ackermann, M.; Pallansch, M.A.; Metzler, A. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl. Environ. Microbiol. 2008, 74, 5608–5614. [Google Scholar] [CrossRef] [Green Version]
- Mayr, A.; Munz, E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl. Bakteriol. Orig. 1964, 195, 24–35. [Google Scholar]
- Meyer, H.; Sutter, G.; Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031–1038. [Google Scholar]
- Carroll, M.W.; Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238, 198–211. [Google Scholar] [CrossRef]
- Blanchard, T.J.; Alcami, A.; Andrea, P.; Smith, G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J. Gen. Virol. 1998, 79, 1159–1167. [Google Scholar]
- Drexler, I.; Heller, K.; Wahren, B.; Erfle, V.; Sutter, G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79, 347–352. [Google Scholar]
- Stickl, H.; Hochstein-Mintzel, V.; Mayr, A.; Huber, H.C.; Schäfer, H.; Holzner, A. MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 1974, 99, 2386–2392. [Google Scholar] [CrossRef]
- Mayr, A. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis. 2003, 26, 423–430. [Google Scholar] [CrossRef]
- Webster, D.P.; Dunachie, S.; Vuola, J.M.; Berthoud, T.; Keating, S.; Laidlaw, S.M.; McConkey, S.J.; Poulton, I.; Andrews, L.; Andersen, R.F.; et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 2005, 102, 4836–4841. [Google Scholar]
- Cebere, I.; Dorrell, L.; McShane, H.; Simmons, A.; McCormack, S.; Schmidt, C.; Smith, C.; Brooks, M.; Roberts, J.E.; Darwin, S.C.; et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24, 417–425. [Google Scholar] [CrossRef]
- Gilbert, S.C.; Moorthy, V.S.; Andrews, L.; Pathan, A.A.; McConkey, S.J.; Vuola, J.M.; Keating, S.M.; Berthoud, T.; Webster, D.; McShane, H.; Hill, A.V.S. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24, 4554–4561. [Google Scholar]
- Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847–10851. [Google Scholar] [CrossRef]
- Sutter, G.; Wyatt, L.S.; Foley, P.L.; Bennink, J.R.; Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032–1040. [Google Scholar] [CrossRef]
- Drillien, R.; Spehner, D.; Hanau, D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 2004, 85, 2167–2175. [Google Scholar]
- Liu, L.; Chavan, R.; Feinberg, M.B. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008, 9, 15. [Google Scholar] [CrossRef]
- Coulibaly, S.; Brühl, P.; Mayrhofer, J.; Schmid, K.; Gerencer, M.; Falkner, F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341, 91–101. [Google Scholar] [CrossRef]
- Hess, R.D.; Weber, F.; Watson, K.; Schmitt, S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012, 30, 2715–2727. [Google Scholar] [CrossRef]
- Jordan, I.; Vos, A.; Beilfuss, S.; Neubert, A.; Breul, S.; Sandig, V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27, 748–756. [Google Scholar] [CrossRef]
- Jordan, I.; Northoff, S.; Thiele, M.; Hartmann, S.; Horn, D.; Höwing, K.; Bernhardt, H.; Oehmke, S.; Von Horsten, H.; Rebeski, D.; et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39, 50–58. [Google Scholar] [CrossRef]
- Jordan, I.; Sandig, V. Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses. BMC Proc. 2011, 5 Suppl 8, O1. [Google Scholar] [CrossRef]
- Antoine, G.; Scheiflinger, F.; Dorner, F.; Falkner, F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244, 365–396. [Google Scholar] [CrossRef]
- Antoine, G.; Scheiflinger, F.; Dorner, F.; Falkner, F.G. Corrigendum to “The complete genomic sequence of the modified vaccinia Ankara (MVA) strain: Comparison with other orthopoxviruses” [Virology 244 (1998) 365–396]. Virology 2006, 350, 501–502. [Google Scholar] [CrossRef]
- Goebel, S.J.; Johnson, G.P.; Perkus, M.E.; Davis, S.W.; Winslow, J.P.; Paoletti, E. The complete DNA sequence of vaccinia virus. Virology 1990, 179, 247–266. [Google Scholar] [CrossRef]
- Jordan, I.; Horn, D.; Oehmke, S.; Leendertz, F.H.; Sandig, V. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res. 2009, 145, 54–62. [Google Scholar] [CrossRef]
- Jordan, I.; Munster, V.J.; Sandig, V. Authentication of the R06E fruit bat cell line. Viruses 2012, 4, 889–900. [Google Scholar] [CrossRef]
- Appleyard, G.; Hapel, A.J.; Boulter, E.A. An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol. 1971, 13, 9–17. [Google Scholar] [CrossRef]
- Plotkin, S.A. Vaccines: The fourth century. Clin. Vaccine Immunol. 2009, 16, 1709–1719. [Google Scholar] [CrossRef]
- Harrison, S.C.; Alberts, B.; Ehrenfeld, E.; Enquist, L.; Fineberg, H.; McKnight, S.L.; Moss, B.; O’Donnell, M.; Ploegh, H.; Schmid, S.L.; et al. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. USA 2004, 101, 11178–11192. [Google Scholar]
- Moss, B. Poxvirus cell entry: How many proteins does it take? Viruses 2012, 4, 688–707. [Google Scholar] [CrossRef]
- Byrd, C.M.; Bolken, T.C.; Hruby, D.E. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 2002, 76, 8973–8976. [Google Scholar] [CrossRef]
- Heljasvaara, R.; Rodríguez, D.; Risco, C.; Carrascosa, J.L.; Esteban, M.; Rodríguez, J.R. The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles. J. Virol. 2001, 75, 5778–5795. [Google Scholar] [CrossRef]
- Kato, S.E.M.; Strahl, A.L.; Moussatche, N.; Condit, R.C. Temperature-sensitive mutants in the vaccinia virus 4b virion structural protein assemble malformed, transcriptionally inactive intracellular mature virions. Virology 2004, 330, 127–146. [Google Scholar] [CrossRef]
- Yeh, W.W.; Moss, B.; Wolffe, E.J. The vaccinia virus A9L gene encodes a membrane protein required for an early step in virion morphogenesis. J. Virol. 2000, 74, 9701–9711. [Google Scholar] [CrossRef]
- Husain, M.; Weisberg, A.S.; Moss, B. Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 2007, 366, 424–432. [Google Scholar] [CrossRef]
- Blasco, R.; Sisler, J.R.; Moss, B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol. 1993, 67, 3319–3325. [Google Scholar]
- Katz, E.; Wolffe, E.; Moss, B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J. Virol. 2002, 76, 11637–11644. [Google Scholar]
- Meiser, A.; Boulanger, D.; Sutter, G.; Krijnse Locker, J. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J. Gen. Virol. 2003, 84, 1383–1392. [Google Scholar] [CrossRef]
- Lohr, V.; Rath, A.; Genzel, Y.; Jordan, I.; Sandig, V.; Reichl, U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27, 4975–4982. [Google Scholar] [CrossRef]
- Smith, G.L.; Vanderplasschen, A.; Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002, 83, 2915–2931. [Google Scholar]
- Schmidt, F.I.; Bleck, C.K.E.; Mercer, J. Poxvirus host cell entry. Curr. Opin. Virol. 2012, 2, 20–27. [Google Scholar] [CrossRef]
- Wolf, M.W.; Reichl, U. Downstream processing of cell culture-derived virus particles. Expert Rev. Vaccines 2011, 10, 1451–1475. [Google Scholar] [CrossRef]
- Schmidt, F.I.; Bleck, C.K.E.; Helenius, A.; Mercer, J. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 2011, 30, 3647–3661. [Google Scholar] [CrossRef]
- Carter, G.C.; Law, M.; Hollinshead, M.; Smith, G.L. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J. Gen. Virol. 2005, 86, 1279–1290. [Google Scholar] [CrossRef]
- Blasco, R.; Moss, B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 1991, 65, 5910–5920. [Google Scholar]
- Chen, Y.; Honeychurch, K.M.; Yang, G.; Byrd, C.M.; Harver, C.; Hruby, D.E.; Jordan, R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009, 6, 44. [Google Scholar] [CrossRef]
- Vliegen, I.; Yang, G.; Hruby, D.; Jordan, R.; Neyts, J. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antiviral Res. 2012, 93, 160–166. [Google Scholar] [CrossRef]
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Jordan, I.; Horn, D.; John, K.; Sandig, V. A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium. Viruses 2013, 5, 321-339. https://doi.org/10.3390/v5010321
Jordan I, Horn D, John K, Sandig V. A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium. Viruses. 2013; 5(1):321-339. https://doi.org/10.3390/v5010321
Chicago/Turabian StyleJordan, Ingo, Deborah Horn, Katrin John, and Volker Sandig. 2013. "A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium" Viruses 5, no. 1: 321-339. https://doi.org/10.3390/v5010321